Ocular Therapeutix (NasdaqGM:OCUL) Conference March 25, 2026 09:30 AM ET Company ParticipantsLisa Walter - VP of Biotech Equity ResearchPravin Dugel - Executive Chairman, President, and CEOLisa WalterGood morning, everyone. I'm Lisa Walter, Biotech Analyst here at RBC Capital Markets. Thanks for joining us at RBC's Ophthalmology Conference. This session, we have Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix. Pravin, thanks so much for joining us today. How are you doing?Pravin D ...

Summary of Ocular Therapeutix FY Conference Call Company Overview - **Company**: Ocular Therapeutix (NasdaqGM: OCUL) - **Event**: FY Conference on March 02, 2026 - **Key Speaker**: Pravin U. Dugel, CEO Core Industry Insights - **Industry**: Biopharmaceuticals, specifically focusing on retinal diseases and treatments - **Key Product**: AXPAXLI, a drug aimed at treating retinal diseases, with a focus on its superiority over existing anti-VEGF treatments Key Points and Arguments 1. **Positive Study Outcome**: The SOL-1 study achieved a positive outcome, marking the first superiority study in the retina field to meet its primary endpoint, with a p-value of 0.0006, indicating statistical significance [2][8][25] 2. **Study Design**: The study was conducted under a Special Protocol Assessment (SPA) from the FDA, making it unique and unprecedented in its design [2][25] 3. **Data Transparency**: Ocular Therapeutix provided extensive data (129 slides) to address questions and concerns raised post-study announcement, emphasizing the consistency of the data across various analyses [3][4][5] 4. **Visual Acuity Loss**: The study highlighted the time it takes for significant vision loss to occur, with a focus on the clinical significance of the OCT results, which showed a high degree of disease control [8][20] 5. **Rescue Patients Analysis**: The analysis of patients who required rescue injections indicated that the AXPAXLI drug performed well even in a biased patient population, with results still being favorable compared to EYLEA [17][19] 6. **Superiority Label Importance**: The CEO emphasized the potential for AXPAXLI to receive a superiority label, which would protect its pricing and market position against competitors, particularly in a landscape filled with non-inferiority studies [25][27] 7. **Community vs. Clinical Trial Performance**: The CEO expressed confidence that AXPAXLI would perform better in real-world settings than in clinical trials, as the trial population was designed to lose vision [32][33] 8. **Regulatory Pathway**: Ocular Therapeutix is optimistic about submitting for approval based on a single trial, citing the robustness of their data and the SPA agreement with the FDA [64][65] 9. **Broad Label Expectations**: The company anticipates a broad label for diabetic retinopathy and diabetic macular edema, which would encompass all patients with these conditions [66][67] Additional Important Insights - **Safety Profile**: The CEO addressed concerns regarding floaters and cataracts, clarifying that reported floaters were drug particles observed by physicians and did not affect vision [60][63] - **Market Positioning**: The company aims to differentiate AXPAXLI from competitors like EYLEA and Vabysmo, highlighting its longer duration of effect and potential for better patient outcomes [48][49] - **Physician Perspectives**: There is a disconnect between analysts' focus on labeling and physicians' practical use of the drug, with physicians prioritizing treatment efficacy over label specifics [22][23][27] This summary encapsulates the key discussions and insights from the Ocular Therapeutix conference call, focusing on the company's recent study outcomes, product positioning, and future regulatory strategies.

Core Insights - The biotech industry experienced significant developments this week, including FDA approvals, clinical trial results, and licensing agreements, indicating a dynamic landscape for investment opportunities and advancements in healthcare [1]. FDA Approvals & Rejections - NRx Pharmaceuticals is on track for FDA approval of NRX-100, with existing clinical data and real-world evidence from over 65,000 patients potentially supporting a New Drug Application (NDA) under Fast Track Designation [2][3]. - Kane Biotech received FDA clearance for its Revyve Antimicrobial Skin and Wound Cleanser, which targets wound bacteria and biofilms, with plans for manufacturing scale-up in 2026 [4][5]. - Johnson & Johnson's RYBREVANT FASPRO received FDA approval for a simplified monthly dosing schedule, enhancing treatment options for patients with advanced non-small cell lung cancer [6][7]. - Spruce Biosciences reported positive feedback from FDA Type B meetings for its enzyme replacement therapy for Sanfilippo syndrome type B, with a targeted BLA filing in Q4 2026 [8][9]. - Moderna's seasonal influenza vaccine submission (mRNA-1010) is under FDA review, with a PDUFA date set for August 5, 2026, aiming for availability in the 2026/2027 flu season [10][11]. - Disc Medicine received a Complete Response Letter (CRL) for its NDA for Biopertin in erythropoietic protoporphyria, citing insufficient correlation with sunlight exposure endpoints [13][14]. - AbbVie and Genentech's combination regimen of VENCLEXTA and Acalabrutinib for chronic lymphocytic leukemia (CLL) received FDA approval, showing a 35% reduction in disease progression risk compared to standard treatment [15][16]. Deals - Theriva Biologics entered an exclusive licensing agreement with Rasayana Therapeutics for SYN-020, receiving a $3 million upfront payment and potential milestone payments totaling up to $38 million [17][18]. - Sensei Biotherapeutics acquired Faeth Therapeutics, expanding its oncology portfolio with the investigational asset PIKTOR, and announced a concurrent private placement of $200 million to advance clinical milestones [19][20]. Clinical Trials - Breakthroughs - Eli Lilly's Taltz and Zepbound combination therapy showed positive results in a Phase 3 trial for plaque psoriasis and obesity, achieving superior outcomes compared to Taltz alone [21][22]. - Zealand Pharma reported positive Phase 1a results for ZP9830, a Kv1.3 channel blocker, demonstrating safety and tolerability in healthy volunteers [23][24]. - Novartis' Remibrutinib met primary endpoints in a Phase 3 trial for chronic inducible urticaria, showing significant response rates compared to placebo [26][27]. - Ocular Therapeutix's AXPAXLI demonstrated superiority over aflibercept in a Phase 3 trial for wet age-related macular degeneration, although stock prices fell due to investor disappointment [28][29]. - Rallybio's RLYB116 Phase 1 study showed promising results for immune platelet transfusion refractoriness, with plans for a Phase 2 trial in 2026 [31][32]. - Teva and Sanofi's Duvakitug Phase 2b trial demonstrated durable efficacy in ulcerative colitis and Crohn's disease, reinforcing the rationale for ongoing Phase 3 programs [35][36]. - Genentech's Gazyva met primary endpoints in a Phase III study for primary membranous nephropathy, showing significant remission rates compared to tacrolimus [38][39].

Core Insights - AXPAXLI has demonstrated superiority over aflibercept in a Phase 3 trial for wet AMD, achieving significant visual acuity maintenance at both Week 36 and Week 52 [1][2][3] Group 1: Trial Results - The primary endpoint was met with 74.1% of subjects in the AXPAXLI arm maintaining vision at Week 36, showing a 17.5% risk difference (p=0.0006) compared to aflibercept [1][7] - At Week 52, 65.9% of subjects treated with AXPAXLI maintained vision, with a 21.1% risk difference (p<0.0001) compared to aflibercept [1][9] - Rescue-free rates for AXPAXLI were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52, respectively, compared to 72.1%, 56.4%, and 47.7% for aflibercept [1][11] Group 2: Safety Profile - AXPAXLI was generally well-tolerated with no treatment-related ocular serious adverse events (SAEs) reported [5][19] - The safety profile included a lower incidence of ocular adverse events compared to aflibercept, with only one SAE in the AXPAXLI arm [5][38] Group 3: Future Plans - The company plans to submit a New Drug Application (NDA) based on the SOL-1 data, pending discussions with the U.S. FDA [2][19] - Detailed results will be presented at the 49th Macula Society Annual Meeting scheduled for February 25-28, 2026 [16][20] Group 4: Mechanism and Technology - AXPAXLI is a bioresorbable intravitreal hydrogel incorporating axitinib, a multi-target tyrosine kinase inhibitor with anti-angiogenic properties [21][30] - The trial was conducted under a Special Protocol Assessment (SPA) agreement with the FDA, aiming for a superiority label for AXPAXLI in wet AMD [4][25] Group 5: Market Context - Wet AMD is a leading cause of severe vision loss, affecting approximately 14.8 million individuals globally, with current therapies facing challenges such as treatment burden and patient discontinuation [29] - AXPAXLI's potential to reduce treatment burden and improve long-term visual outcomes could lead to significant clinical adoption if approved [3][4]

Core Viewpoint - Ocular Therapeutix Inc. (NASDAQ:OCUL) is identified as a low-priced stock with significant upside potential, particularly due to its drug AXPAXLI, which targets wet AMD and diabetic retinopathy [1][3]. Group 1: Regulatory Strategy and Drug Development - On December 8, Ocular Therapeutix announced an acceleration of its regulatory strategy for AXPAXLI, planning to submit a New Drug Application (NDA) shortly after receiving one-year data from its SOL-1 Phase 3 trial, contingent on positive results [2]. - The topline results from the SOL-1 trial are expected to be released in Q1 2026 [2]. - The FDA has provided guidance indicating that a single, well-powered registrational trial may be sufficient for approval, which could expedite the regulatory process for AXPAXLI [3]. Group 2: Clinical Trial Details - The SOL-1 study, which completed randomization in December 2024, involves 344 treatment-naïve subjects and compares AXPAXLI against a 2 mg dose of aflibercept [3]. - The primary endpoint of the SOL-1 trial measures the proportion of patients maintaining visual acuity at week 36, supporting the drug's potential for a superiority label [3]. Group 3: Market Position and Analyst Sentiment - Bank of America has raised the price target for Ocular Therapeutix from $18 to $21 while maintaining a Buy rating, reflecting optimism about the company's development strategy and competitive advantages [1]. - The firm hosted CEO Pravin Dugel to discuss upcoming corporate milestones, reinforcing confidence in the company's direction [1]. Group 4: Company Overview - Ocular Therapeutix is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases and other eye conditions using bioresorbable hydrogel-based formulation technology in the US [4].

Core Viewpoint - Ocular Therapeutix Inc. is highlighted as a promising biotech stock by Wall Street analysts, with a recent price target increase from $19 to $21 by H.C. Wainwright, reflecting confidence in the company's future prospects following a significant FDA submission [1][3]. Group 1: Company Developments - Ocular Therapeutix has submitted a new drug application for AXPAXLI, a 450 µg axitinib intravitreal implant, which is expected to enhance its market position [3]. - The FDA has indicated that only one pivotal clinical trial will be required for new drug approvals, which is a positive development for Ocular Therapeutix [3]. - The company is set to deliver topline results from its Phase 3 SOL-1 trial in the first quarter of the next year, utilizing the 505(b)(2) regulatory pathway to potentially expedite the review process for AXPAXLI [4]. Group 2: Leadership Insights - Pravin U. Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, expressed the company's commitment to innovation in retina treatments and indicated plans to submit the NDA for AXPAXLI for wet AMD shortly after the SOL-1 trial results, assuming they are positive [5]. Group 3: Product Focus - Ocular Therapeutix specializes in developing, manufacturing, and selling innovative eye treatments for serious eye diseases, employing proprietary hydrogel technology to deliver drugs directly to the eye, which enhances treatment efficacy for conditions such as wet AMD, glaucoma, and post-surgery pain/inflammation [5].

Group 1 - U.S. stocks experienced a decline, with the Dow Jones falling over 200 points on Monday [1] - Paramount Skydance Corporation launched an all-cash tender offer to acquire Warner Bros. Discovery, Inc. for $30 per share, valuing the company at $108.4 billion [1] - Paramount aims to create a scaled Hollywood leader by merging with Warner Bros. [1] Group 2 - Paramount Skydance shares increased by 9.8% to $14.68 on Monday [2] - Other notable stocks that gained include Wave Life Sciences Ltd., which rose 129.1% to $17.16 after positive interim Phase 1 data for its obesity drug [4] - Structure Therapeutics Inc. saw a gain of 100.5% to $69.30 following the announcement of topline data from its clinical program for obesity treatment [4] Group 3 - Fulcrum Therapeutics, Inc. shares rose 62.3% to $14.44 after reporting initial results from its Phase 1b trial for sickle cell disease [4] - Kymera Therapeutics, Inc. gained 51.2% to $100.75 after reporting successful trial results for its KT-621 drug [4] - Confluent, Inc. shares increased by 29.2% to $29.89 after IBM agreed to acquire the company for $31 per share [4]

Summary of Ocular Therapeutix FY Conference Call Company Overview - **Company**: Ocular Therapeutix (NasdaqGM: OCUL) - **Focus**: Primarily on ophthalmology, specifically retina treatments - **Location**: Bedford, Massachusetts - **Key Product**: AXPAXLI, targeting retinal vascular diseases [2][3] Core Points and Arguments Clinical Trials - **Phase III Studies**: Two ongoing studies, SOL-1 and SOLAR - **SOL-1**: Expected readout in Q1 2026, aimed at obtaining a superiority label for wet macular degeneration [2][6] - **SOLAR**: Expected readout in H1 2027, designed for clinical relevance and will be analyzed alongside SOL-1 [2][7] Treatment Challenges - **Sustainability**: 40% of patients with retinal diseases are not receiving treatment, leading to blindness [3][20] - **Long-term Outcomes**: Current treatments lead to deterioration in vision over time due to pulsatile treatment effects [4][20] Product Development Strategy - **Superiority Label**: AXPAXLI aims to achieve a superiority label, which is crucial for market adoption and clinician preference [10][16] - **Durability**: Targeting a product profile that allows for treatment every six to twelve months, with expected durability of nine to ten months [12][13] Market Positioning - **Competitive Advantage**: AXPAXLI is positioned to provide more data than any other drug in the market, enhancing its commercial leverage [9][18] - **Intellectual Property**: IP extension granted until 2044, providing a strategic advantage against future competitors [17][18] Patient Selection and Recruitment - **De-risking Patient Population**: Thoughtful selection of patients for trials to minimize variability and enhance trial outcomes [22][29] - **Efficient Recruitment**: Record-time recruitment for both studies, indicating strong interest and potential for successful outcomes [29] Addressing Unmet Needs - **Diabetic Retinopathy**: AXPAXLI could significantly reduce the rate of vision-threatening complications from 30%-40% to potentially zero with annual injections [31][32] - **Regulatory Endpoint**: Introduction of a novel ordinal endpoint for diabetic retinopathy studies, which is clinically relevant and agreed upon by the FDA [34] Other Important Insights - **FDA Alignment**: Ocular Therapeutix emphasizes alignment with FDA guidelines to mitigate regulatory risks [6][25] - **Market Dynamics**: The company is aware of the competitive landscape and is strategically positioning AXPAXLI to address both clinician and patient needs effectively [18][30] This summary encapsulates the key points discussed during the Ocular Therapeutix FY Conference Call, highlighting the company's strategic focus, clinical trial progress, and market positioning.

Summary of Ocular Therapeutix Conference Call Company Overview - **Company**: Ocular Therapeutix (NasdaqGM: OCUL) - **Focus**: Development of innovative therapies for retinal diseases, particularly through their lead program AXPAXLI Key Points and Arguments Clinical Trials and Drug Development - Ocular Therapeutix is currently conducting two pivotal Phase III clinical trials: SOL-1 (superiority study) and SOLAR (non-inferiority study) [3][10] - SOL-1 results are expected in Q1 2026, while SOLAR results are anticipated in the first half of 2027 [3][4] - AXPAXLI is a TKI (tyrosine kinase inhibitor) on an attunable hydrogel platform, showing promising results in studies conducted in Australia and the U.S. [5][6] - AXPAXLI is reported to be 100 times more potent and 50 times more selective than other TKIs [5] Unmet Needs in Retinal Diseases - There is a significant dropout rate of 40% in wet macular degeneration treatments, leading to blindness for many patients [6] - AXPAXLI aims to provide a sustainable treatment option, allowing for annual injections instead of monthly or bi-monthly visits [8] - For diabetic retinopathy, less than 1% of patients currently receive treatment, despite the high risk of complications [7][30] Confidence in Clinical Trial Design - The design of SOL-1 and SOLAR trials follows FDA guidelines, with a focus on de-risking patient populations [12][15] - SOL-1 has a rescue-free rate of 100% at six months and 80% at twelve months, indicating strong efficacy [11] - The superiority label is considered a significant advantage, as it differentiates AXPAXLI from other anti-VEGF treatments [16][18] Regulatory Pathway - Ocular Therapeutix plans to utilize a 505(b)(2) regulatory pathway for expedited approval, leveraging existing FDA-approved components of AXPAXLI [28][29] - The company expects to submit for approval immediately after successful SOLAR results [28] Market Opportunity - The target market for diabetic retinopathy is estimated to be 3.5 times larger than that for wet macular degeneration, with a substantial unmet need [30] - AXPAXLI is designed to address both diabetic retinopathy and diabetic macular edema, potentially leading to a broad label for treatment [32][38] Commercial Strategy - Ocular Therapeutix has an existing product, Dextenza, which provides a foundation for scaling up their commercial efforts in ophthalmology [39] - The company is well-capitalized and does not currently see a need for partnerships or licensing opportunities for the commercialization of AXPAXLI [40] Additional Important Information - The company has a strong intellectual property position, with extensions to 2044, enhancing the attractiveness of AXPAXLI [17] - The novel ordinal endpoint for diabetic retinopathy studies has been accepted by the FDA, increasing the likelihood of successful outcomes in future trials [34][35] This summary encapsulates the critical insights from the Ocular Therapeutix conference call, highlighting the company's strategic direction, clinical advancements, and market potential in the field of retinal diseases.

Group 1 - Ocular Therapeutix Inc. (NASDAQ:OCUL) is recognized as a promising healthcare stock with significant upside potential, receiving a price target increase from H.C. Wainwright to $19 from $15 while maintaining a Buy rating [1][2] - The price target adjustment follows the FDA granting a Special Protocol Assessment (SPA) for Ocular Therapeutix's AXPAXLI, aimed at treating non-proliferative diabetic retinopathy (NPDR) [2][3] - The company presented the design of two Phase 3 superiority trials, HELIOS-2 and HELIOS-3, during its investor day, which are critical for the evaluation of AXPAXLI [2][3] Group 2 - HELIOS-2 is a two-arm trial comparing a single AXPAXLI injection to a single ranibizumab injection, while HELIOS-3 is a three-arm trial comparing two dosing regimens of AXPAXLI to a sham treatment [3] - The updated financial model anticipates potential sales of AXPAXLI in NPDR, projecting the company's market value at $3.97 billion, equating to $19 per share [3] - Ocular Therapeutix is a biopharmaceutical company focused on developing therapies for eye-related conditions, with a product pipeline that includes Dextenza, OTX-TP, and OTX-TIC [4]